Phase I Trial of Cediranib (AZD2171), An Orally Bioavailable Antiangiogenic Agent, in Children and Adolescents With Refractory or Recurrent Solid Tumors or Acute Myeloid Leukemia (Acute Myeloid Leukemia Accrual Closed as of 02/19/10)

Trial Profile

Phase I Trial of Cediranib (AZD2171), An Orally Bioavailable Antiangiogenic Agent, in Children and Adolescents With Refractory or Recurrent Solid Tumors or Acute Myeloid Leukemia (Acute Myeloid Leukemia Accrual Closed as of 02/19/10)

Completed
Phase of Trial: Phase I

Latest Information Update: 31 Jan 2017

At a glance

  • Drugs Cediranib (Primary)
  • Indications Acute myeloid leukaemia; Ewing's sarcoma; Germ cell and embryonal neoplasms; Liver cancer; Neuroblastoma; Osteosarcoma; Soft tissue sarcoma; Solid tumours; Wilms' tumour
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 07 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 07 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 07 Oct 2011 Planned end date changed from 1 Apr 2006 to 1 Oct 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top